Celyad treats first patient of second cohort in NKG2D CAR T-CELL Phase I Trial

Celyad treats first patient of second cohort in NKG2D CAR T-CELL Phase I Trial

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CAR T-Cell Phase I Trial

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CAR T-Cell Phase I Trial

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad

Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I Trial

Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I Trial

Cardio3 BioSciences Announces Infusion of First Patient in NKG2D Phase I Trial

Cardio3 BioSciences Announces Infusion of First Patient in NKG2D Phase I Trial

Cardio3 BioSciences Enrolls First Patient in Phase I Trial for NKG2D CAR T-Cell

Cardio3 BioSciences Enrolls First Patient in Phase I Trial for NKG2D CAR T-Cell

Cardio3 BioSciences receives USPTO Notice of Allowance for first U.S. patent broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen receptor 

Cardio3 BioSciences receives USPTO Notice of Allowance for first U.S. patent broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen receptor